Podcasts about gastric cancer

JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, everyone, and welcome to our 2025 ASCO Annual Meeting Series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, JCO Editorial Fellow, and I'm joined by Dr. Andrew Ko, JCO Associate Editor, to discuss the Journal of Clinical Oncology article and abstract presentation "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Now, let's start off with the relevance of this article. Andrew, can you please explain this to our listeners? Dr. Andrew Ko: Sure. Thanks, Peter. So, this was a very large international study evaluating the combination of lenvatinib and pembrolizumab. And just for context, that combination has been approved for use in other solid tumor types. It's FDA approved for renal cell carcinoma, for example, and endometrial carcinoma. But this study was looking specifically at this combination together with a chemotherapy backbone - so either FOLFOX or CAPOX - and comparing that to what at the time was a standard of care, which was just standard chemotherapy by itself. So, this very large study was intending to look at this particular novel combination. And we can get into some of the nuances of this study because the way that the experimental, the combination arm, was designed was perhaps a little bit more on the unusual side and led to maybe some imbalance in terms of how we think about the respective arms. Dr. Peter Li: Okay. We can definitely talk more about that as we go on. So, what are some of the key results of this study, and how do you think this will impact practice in the future? Dr. Andrew Ko: That's a good question. Technically, it was not a positive study. Well, it was positive in the sense that the co-primary endpoints - which included both progression-free survival and overall survival - so, progression-free survival, it did technically meet its endpoint, both in terms of the overall population and the preplanned subgroup analysis of patients who had a PD-L1 CPS of greater than or equal to 1. So, there was a PFS benefit with the experimental combination - the lenvatinib, pembrolizumab, plus chemotherapy - compared to chemotherapy alone. I will say the benefit was on the more modest side. So, if you even look at the medians, it was not a marked difference. If you look at the hazard ratios, they did meet statistical significance. On the other hand, this did not translate into a benefit for overall survival. So, when you ask, "Well, is this going to inform practice?" I'd have to say no. It highlights, I think, that JCO does want to publish articles that aren't necessarily going to be practice-changing, but that I think offer a lot of insights into trial design and important aspects of investigating novel treatments, even if they don't end up moving the needle in routine clinical practice. Dr. Peter Li: I totally agree with you. I mean, it was significant in terms of progression-free survival, but again, not clinically significant. And then overall survival, the interventional arm actually appeared to do slightly worse overall. Can you make some comments on the strengths and the weaknesses of this study, and where do you see us going from here? Dr. Andrew Ko: So, I think a couple of things worth highlighting in this study, very well designed, more than 800 patients in total. So, first of all, as I mentioned at the beginning, the combination was a little bit unique in terms of patients enrolled to the experimental arm got the combination of lenvatinib, pembrolizumab, together with chemotherapy for a very finite duration. So, that period of chemotherapy they received was only three months. And per protocol, patients then just segued to, quote unquote “maintenance treatment” with just the lenvatinib and pembrolizumab combination. Whereas patients on the control arm, meaning chemotherapy alone, would continue chemotherapy basically in perpetuity until their disease progressed or intolerable toxicity. So, there really was an imbalance in terms of, if you think that chemotherapy or continuing chemotherapy beyond that initial three-month period of time may be significant, that could have had some impact on the robustness or the efficacy of the experimental arm. There were some other aspects in terms of perhaps some differences in the rates of post-progression treatment, in other words, patients going on to receive second-line treatment. I think the other very relevant aspect, Peter, in this study was that the control arm - and no fault of the investigators - but the control arm at the time the study was ongoing just consisted of chemotherapy, FOLFOX CAPOX, by itself, without an immune checkpoint inhibitor, right? And we clearly know, based on results of several large phase III studies, and it's now in standard clinical practice, that we routinely use chemotherapy plus an immune checkpoint inhibitor. Certainly for patients with CPS PD-1/PD-L1 scores that are, well, you could argue greater than 1, or perhaps greater than 5 or 10. But the point being that the control arm of the study probably doesn't reflect what is currently used in clinical practice. And that's just always a challenge in clinical trial design, right? That when a study is designed and when it rolls out, you're always at risk in a rapidly changing and moving field that the standard of care may evolve during the lifetime of that particular trial, which is what I think you see in LEAP-015. Dr. Peter Li: Totally understand. And the survival we see from this study is also roughly similar to the combination of immuno-chemotherapy that is the standard of care today, which is, the authors mentioned, 12 to 14 months. Thank you so much, Andrew, for your input and for speaking about the JCO article "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

- Overview of Gastric Cancer, Including Diagnosis & Staging - Current Standard of Care, Including Chemotherapy - New Treatment Approaches & the Role of Targeted Treatment & Immunotherapy - Precision Medicine: Predicting Response to Treatment - The Role of Clinical Trials: How Research Contributes to Treatment Options - Controlling Treatment Side Effects, Symptoms, Discomfort, & Pain - The Importance of Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments Including, Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Gastric Cancer, Including Diagnosis & Staging - Current Standard of Care, Including Chemotherapy - New Treatment Approaches & the Role of Targeted Treatment & Immunotherapy - Precision Medicine: Predicting Response to Treatment - The Role of Clinical Trials: How Research Contributes to Treatment Options - Controlling Treatment Side Effects, Symptoms, Discomfort, & Pain - The Importance of Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments Including, Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Gastric Cancer, Including Diagnosis & Staging - Current Standard of Care, Including Chemotherapy - New Treatment Approaches & the Role of Targeted Treatment & Immunotherapy - Precision Medicine: Predicting Response to Treatment - The Role of Clinical Trials: How Research Contributes to Treatment Options - Controlling Treatment Side Effects, Symptoms, Discomfort, & Pain - The Importance of Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments Including, Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share encouraging preclinical results presented at the American Association for Cancer Research, highlighting the company's novel therapeutic candidate TNX-1700 for gastric cancer. In the study, a murine fusion protein (mTFF2-MSA) was tested, modeling the human fusion version TFF2-HSA currently under development as TNX-1700. Dr. Lederman explained that combining mTFF2-MSA with anti-PD1 immunotherapy significantly reduced tumor immunosuppression in animal models. Specifically, the therapy decreased immunosuppressive neutrophils and cancer-induced granulopoiesis, while stimulating CD8+ T-cell responses that helped inhibit tumor progression. The study also revealed a negative correlation between TFF2 expression and PMN-MDSC levels in gastric cancer patients, supporting the clinical relevance of TFF2 modulation in immuno-oncology. Tonix plans to continue advancing TNX-1700 as a first-in-class fusion protein therapeutic for hard-to-treat cancers. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #TNX1700 #GastricCancer #CancerResearch #Immunotherapy #PD1Blockers #AACR2025 #BiotechNews #OncologyInnovation #CancerTreatment

Join us on SurgOnc Today as we delve into the complexities of surgical treatment for stage IV gastric cancer. This episode explores the latest strategies and considerations for patients with advance disease including patients with positive peritoneal cytology, peritoneal carcinomatosis, liver metastasis and para-aortic nodal disease. We discuss the evolving role of surgery in improving outcomes for these patients. In this episode of SurgOnc today, Ahmed Dehal and Erin Ward from the SSO GI disease site working group Interview Dr. Lordick From University of Leipzig and Dr. Badgwell From MD Anderson Cancer Centre to discuss the topic.

Matters Microbial #83: Helicobacter — Passing the Acid Test March 19, 2025 Today, Dr. Karen Ottemann, Professor and Chair of the Department of Microbiology and Environmental Toxicology at the University of California Santa Cruz joins the #QualityQuorum to discuss the fascinating strategies of Helicobacter pylori, which can cause gastric ulcers and even stomach cancer in people. Host: Mark O. Martin Guest: Karen Ottemann Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An overview of Helicobacter pylori and its relationship to gastric ulcers and gastric cancer. A video on the relationship between Helicobacteri pylori and gastric diseases. The story of how Helicobacter pylori was finally demonstrated to be responsible for gastric ulcers and gastric cancer. The prevalence of Helicobacter pylori world wide. When Helicobacter pylori does not cause disease:  a possible theory. The mechanism by which Helicobacter pylori causes gastric ulcers. The mechanism by which Helicobacter pylori causes gastric cancer. An overview of gastric cancer. An overview of inflammation and cancer. One of the articles from Dr. Ottemann's research group discussed in this episode:  “Bacterial flagella hijack type IV pili proteins to control motility.” Another of the articles from Dr. Ottemann's research group discussed in this episode:  “Helicobacter pylori cheV1 mutants recover semisolid agar migration due to loss of a previously uncharacterized Type IV filament membrane alignment complex homolog.” Dr. Ottemann's faculty website. Dr. Ottemann's research website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Linda Brubaker, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 22-28, 2025.

In this episode of SurgOnc Today®, Steve Kwon, MD, and Mike Mavros, MD, are joined by Joo Ha Hwang, MD, and Yanghee Woo, MD, for a discussion of managing patients at high-risk of gastric cancer development at the population-level and at the patient-level. The panel will also discuss nonoperative and operative strategies in managing precancerous gastric lesions and early gastric cancers.

CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-advanced-gastric-cancer-best-practices-for-biomarker-directed-treatment-approachesa-case-study/29848/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

Dr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

Send us a textStomach cancer, often referred to as gastric cancer, is a sneaky cancer.  Its symptoms can be easily mistaken for more benign conditions like indigestion or acid reflux, making early detection a challenge. In our latest podcast episode, we delve into this complex disease with the help of two esteemed experts: gastroenterologist Dr. Walid Chaloub, and Dr. Ritu Mukherji, a medical oncologist from MedStar Georgetown Cancer Institute in D.C. Host Debra Schindler explores the biology of stomach cancer with her physician guests to understand how mutations in the DNA of stomach cells can lead to uncontrolled growth and tumor formation. This formidable disease often goes unnoticed until it has advanced significantly, highlighting the critical need for awareness and early detection. Dr. Mukherji shares the various risk factors associated with stomach cancer, including smoking, diet, and certain bacterial infections like H. Pylori. She emphasizes the importance of molecular testing in diagnosing and treating this disease, as it can reveal specific mutations that may be targeted with personalized therapies. The episode also explores the different diagnostic tools available, such as endoscopy and CT scans, and the role of tumor markers in assessing the presence of cancer. While these tools are invaluable, Dr. Mukherji stresses that they are not foolproof, underscoring the importance of comprehensive testing and expert analysis. One of the most enlightening parts of the discussion is the potential for treatment and even cure. While surgery is a common approach, not all patients are candidates. The podcast highlights the evolving role of chemotherapy, immunotherapy, and targeted therapies, offering hope to those battling this disease. Listeners will gain a deeper understanding of the symptoms to watch for, the importance of genetic predispositions, and the latest advancements in treatment. This episode is a must-listen for anyone interested in learning more about stomach cancer, whether for personal knowledge or to support a loved one. Tune in to this informative episode to arm yourself with the knowledge needed to recognize the signs of stomach cancer early and explore the treatment options available. Your Health, or that of someone you care about, could depend on it.---For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Michael Bouvet and Dr. Kristin Cox the applicability of M5A-IR800 to target human gastric cancer, as reported in their article, "Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody."

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Michael Bouvet and Dr. Kristin Cox the applicability of M5A-IR800 to target human gastric cancer, as reported in their article, "Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody."

Innovative Ansätze in der Onkologie verdienen besondere Aufmerksamkeit. In dieser Folge bespreche ich gemeinsam mit Prof. Hünerbein aus Oranienburg die Ergebnisse einer retrospektiven Kohortenstudie aus den USA. Im Fokus steht der Einsatz der laparoskopischen HIPEC-Therapie bei Magenkrebs mit Peritonealmetastasen – ein Verfahren, das vielversprechende Sicherheit und perioperative Ergebnisse zeigt und die chirurgische Onkologie bereichern könnte. Viel Freude beim Hören! Moderation: Christoph Paasch Gast: Prof. Dr. med. Peter Hünerbein (Oranienburg) Besprochene Publikation: Read MD, Drake J, Hashemipour G, et al. Initial Experience Using Laparoscopic HIPEC for Gastric Cancer with Peritoneal Metastasis: Safety and Outcomes. Ann Surg Oncol. 2024;31:3750–3757. doi: 10.1245/s10434-024-15102-5. Unter folgendem Link können bei der Landesärztekammer Brandenburg 2 Fortbildungspunkte erworben werden. Der Kursinhalt umfasst stets 3 Folgen: https://lernportal.laekb.de/goto.php?target=crs_3487&client_id=laekb.

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/GI).

Did you know that a bacteria found in the gut of nearly half of the population is a contributor to peptic ulcers, gastric cancers and various other conditions? Is there anything we can DO about this highly transmissable bacteria?  Find out on this episode of Science Matters w/ Reed Davis and Dr. Aron Gonshor. Learn more about Functional Diagnostic Nutrition at fdntraining.com/resources. 

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from September 28-October 4, 2024.

Gastric cancer is a leading cause of cancer death globally. Chronic H pylori infection is the primary cause of gastric cancer, responsible for at least 80% of the new cases. Constanza Camargo, PhD, of the National Cancer Institute joins JAMA Associate Editor John M. Inadomi, MD, to discuss co-testing with FIT and H pylori stool antigen to help prevent gastric cancer. Related Content: Fecal Immunochemical Test and Helicobacter pylori Stool Antigen Co-Testing Screening for Helicobacter pylori to Prevent Gastric Cancer

Pink Sheet reporters and editors discuss Pfizer's abrupt decision to withdraw Oxbryta (:32), the US FDA's Oncologic Drugs Advisory Committee bringing sponsors of approved products back to discuss labeling changes while competitors are pending (10:46), and the new CEO of a generic industry trade association (27:34). More On These Topics From The Pink Sheet Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited: https://pink.citeline.com/PS155302/Pfizer-Withdraws-Oxbryta-But-Overall-Market-Impact-May-Be-Limited EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets: https://pink.citeline.com/PS155296/EMA-Discusses-Fatal-Events-That-Prompted-Pfizer-To-Pull-Oxbryta-From-Global-Markets New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming: https://pink.citeline.com/PS155285/New-US-FDA-Adcomm-Trend--Approved-Cancer-Meds-Get-Another-Look-When-Competitors-Coming All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer: https://pink.citeline.com/PS155300/All-Comers-No-More-US-FDA-AdComm-Supports-PDL1-Threshold-In-Esophageal-Gastric-Cancer Pazdur Calls For 'Kumbaya' To Standardize ImmunoOncology Biomarkers: https://pink.citeline.com/PS155298/Pazdur-Calls-For-Kumbaya-To-Standardize-ImmunoOncology-Biomarkers New AAM CEO Looking To ‘Force Multiply' For US Generics Industry: https://pink.citeline.com/PS155294/New-AAM-CEO-Looking-To-Force-Multiply-For-US-Generics-Industry

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What's Next for Patients With HER2+ Gastric Cancer

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What's Next for Patients With HER2+ Gastric Cancer

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Teresa Tiano, Honours B.A. - A Challenging Journey: A Patient-Centred Perspective on Gastric Cancer

Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer and esophageal cancer. Joe explains, "As you likely know, in the continuum of cancer drugs, you have chemotherapy on one end that indiscriminately kills everything it touches. On the other end, you have uber-targeted therapies looking at specific drivers of what's driving that specific tumor. In our case at Elevation Oncology, we're focused on what we like to call selected targeted oncology drugs so that we are using the unique characteristics of the tumor to target and meet in a targeted way attempt to kill the tumor for a better outcome for the patient." "Gastric cancer in and of itself was an area where Claudin 18.2 is known to be highly expressed, but for gastric cancer, to your point, there's a huge unmet need. For most patients, once they're in second line or third line, the opportunity for drugs that are available to them today is, unfortunately for all of us, very dismal. We think there's a significant opportunity to utilize a Claudin 18.2 antibiotic drug conjugate for overall better outcomes for patients living with gastric cancer." "We quickly saw an ADC approach as an opportunity to treat a broader range of Claudin 18.2 expression. Now, as I'm sure you're aware, in any target in any tumor, there's always a range of expression for Claudin 18.2. In gastric cancer, it's known that as much as 80% of gastric cancer expressed Claudin 18.2 at some level. With that expression, we think an ADC approach will be able to treat a broader range of expression." #ElevationOncology #ADC #AntibodyDrugConjugate #SolidTumors #Claudin182 #Claudins #Cancer ElevationOncology.com Download the transcript here 

Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer and esophageal cancer. Joe explains, "As you likely know, in the continuum of cancer drugs, you have chemotherapy on one end that indiscriminately kills everything it touches. On the other end, you have uber-targeted therapies looking at specific drivers of what's driving that specific tumor. In our case at Elevation Oncology, we're focused on what we like to call selected targeted oncology drugs so that we are using the unique characteristics of the tumor to target and meet in a targeted way attempt to kill the tumor for a better outcome for the patient." "Gastric cancer in and of itself was an area where Claudin 18.2 is known to be highly expressed, but for gastric cancer, to your point, there's a huge unmet need. For most patients, once they're in second line or third line, the opportunity for drugs that are available to them today is, unfortunately for all of us, very dismal. We think there's a significant opportunity to utilize a Claudin 18.2 antibiotic drug conjugate for overall better outcomes for patients living with gastric cancer." "We quickly saw an ADC approach as an opportunity to treat a broader range of Claudin 18.2 expression. Now, as I'm sure you're aware, in any target in any tumor, there's always a range of expression for Claudin 18.2. In gastric cancer, it's known that as much as 80% of gastric cancer expressed Claudin 18.2 at some level. With that expression, we think an ADC approach will be able to treat a broader range of expression." #ElevationOncology #ADC #AntibodyDrugConjugate #SolidTumors #Claudin182 #Claudins #Cancer ElevationOncology.com Listen to the podcast here 

JCO PO author Dr. Samuel J. Klempner shares insights into his JCO PO article, “PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity across 28-8, 22C3, and SP263 assays”. Host Dr. Rafeh Naqash and Dr. Klempner discuss assessing the analytical comparability of three commercially available PD-L1 assays and two scoring algorithms used to assess PD-L1 status in gastric cancer samples. TRANSCRIPT  Dr. Abdul Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Abdul Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center. Today we are excited to be joined by Dr. Samuel J. Klempner, Director of Gastro Esophageal Medical Oncology and Assistant Professor at Harvard Medical School Mass Gen Cancer Center and author of the JCO Precision Oncology article, “PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.” At the time of this recording, our guest disclosures will be linked in the transcript. Dr. Klempner, welcome to our podcast and thanks for joining us today.  Dr. Samuel J. Klempner: Happy to be here. Thanks for having me. Dr. Abdul Rafeh Naqash: For the sake of this podcast, we'll be using our first names. So, Sam, it was great to see you at ASCO recently, where I believe you presented these data as an abstract as well. Dr. Samuel J. Klempner: Yes, we had a poster presentation for this paper, which was published in parallel with the meeting. Dr. Abdul Rafeh Naqash: Congratulations, and I'm very happy that you chose JCO PO as the destination for these data. So we're going to be talking about a lot of different things today in the context of gastric cancer, which I know you treat very often in your clinic. So could you tell us what the treatment landscape for advanced gastric cancer currently is? Because that goes into the context of why I believe you and your colleagues went ahead with this project.  Dr. Samuel J. Klempner: Yeah, happy to. As you know, unfortunately, half or more of our patients, by the time they come to medical attention for a gastric or GE junction or esophageal adenocarcinomas, unfortunately have advanced disease, often metastatic at presentation. So we have this large population of patients with advanced disease, and over the last couple years, we've actually made some substantial advances in the management and survival of this population. This has been mainly driven by biomarker selection, whether it be adding immunotherapy on top of HER2 therapy, whether it be testing for claudin and seeing the results with claudin directed therapies. And perhaps the vast majority of patients are potentially eligible for immune checkpoint inhibitors. We've seen several phase three trials, perhaps highlighted by CheckMate 649, KEYNOTE 859, rationale studies confirming that there are populations of patients who derive significant survival advantages from the addition of anti PD-1 on top of chemotherapy. So the landscape has really evolved into a biomarker directed world, which is exactly what we hope, because ultimately, the goal is, of course, to match patients with the best drugs at the right time. And that's really the background of where this analytical effort came from.  Dr. Abdul Rafeh Naqash: Thank you for giving us that overview. Going to the second part, which, as you mentioned in your initial overview about the role of immunotherapy, and as we all know, immunotherapy has changed the treatment landscape for a lot of different tumor types. And as clinicians, we often see or ask, what is the PD-L1 positivity for, let's say, lung cancer, which is what I treat, and gastric cancer, which is what you treat. Some of the nuances that we don't necessarily go into when we're looking at those reports is the combined positivity score, the tumor proportion score, or the tumor area positivity. Could you give us an understanding, for the sake of our audience or for the sake of our trainees who might be listening to this podcast, what the CPS, or what the TAP  mean and where they are used in the treatment landscape for biomarker selection in the context of gastric cancer? And how do you approach the different cutoffs for CPS when you're treating an individual in the standard of care setting for gastric cancer? Dr. Samuel J. Klempner: For sure, happy to. So I think eventually it all comes back to patients. When we're sitting in a clinic room with the patient, we want to be able to have features about the tumor that's going to tell us if a therapy is more or less likely to work, maybe if there's a prognostic implication so we have predictive and prognostic biomarkers. And PD-L1 expression does not appear to be particularly prognostic, but it does appear to be predictive of benefit from immune checkpoint inhibitors. Therefore, all of the phase 3 trials that we've seen in some way have linked the biomarker expression to outcomes, whether it's the primary endpoint, whether it's post hoc retrospective analyses, etc. What we've seen is that all of these phase 3 trials have largely used different antibodies to define PD-L1 strata within the trial. So whether that's 22C3,  whether it's 28-8, whether it's 263, those are the predominant antibody clones used to examine PD-L1 expression in tumor samples. And it's been pretty clear across these large phase 3 trials that there is a trend with increasing PD-L1 expression and increasing magnitude of benefit. We see this in the improved hazard ratios in the CPS greater than five or greater than ten versus less than one, etcetera.  However, the scoring systems have varied. There is TPS tumor positivity, which only accounts for tumor cells. There is combined positive score, which accounts for tumor cells and mononuclear infiltrates and involves counting cells. And then perhaps the most recent one is the tumor area positivity, which is essentially a non counting method to look broadly at the area of the sample that is expressing PD-L1. It was on this background that we said, is there analytical concordance among the main antibodies? Our work does not address whether there is difference in clinical outcomes between testing 28-8 and 22C3 and SP263. It is simply a pure analytical comparison of the three antibodies. Is a CPS 5, when you call it by 28-8, somewhat agreeable to a TPS or a TAP greater than five with the same antibody and with a different antibody. So we felt that this was kind of a question that hadn't really been fully addressed in the field and may help contextualize results for clinicians and ultimately cross trial comparisons.  Dr. Abdul Rafeh Naqash: Thank you for that explanation. And you bring forth a very important question. And I remember this example of a patient with lung cancer who had tissue NGS done, and they had a limited gene panel with PD-L1 testing sent that showed a PD-L1 of close to 15 or 20%, and then another NGS panel with a different antibody, suggesting that they had a PD-L1 of close to 60-70%, which significantly changes the overall approach for treatment in the context of blood cancer. Is that something that you experience in gastric cancer also, in terms of variability for CPS, determining what treatment combinations you might be able to put an individual patient on? Dr. Samuel J. Klempner: It's rare that we have samples at any institution tested in multiple methods, but these types of papers and others had looked at some stuff similar and prior to our publication, but we know that there is both spatial heterogeneity. So if you test a tumor versus metastasis, you may have different PD-L1 scoring even in regions of large samples, like surgical resections, there will be some intra tumor heterogeneity in regions of expression. And then we also know that sometimes after therapy, for example, post radiation, there's some data that at the time of surgery, the PD-L1 expression may be higher than what the presurgical sample was. So there's a lot of variables that are factored in. But one thing that wasn't really well known is, across the standard antibodies, how well is the inter assay comparison? There had been some work from a group in Singapore, a very nice paper suggesting that at the higher cut points, the agreement was pretty good across the assays, CPS greater than 5 and greater than 10, and maybe slightly less so at the lower. They had used a different method, which was not really what is standard, and they had used multiplex immunofluorescence or IHC. This is not a validated method for PD-L1 scoring. So that was an open question, sort of. Although they laid a very important piece of data down, we wanted to use the most standard assays and essentially do a very similar analysis, but using the standard scoring criteria. Dr. Abdul Rafeh Naqash: Very interesting. So, could you walk us through the approach of how you looked at this question, what kind of samples you used and what kind of testing algorithms you implemented to look at the cross validation of these three different antibodies? Dr. Samuel J. Klempner: The antibodies were chosen primarily because those are the standard ones that either have companion diagnostics or have been used most commonly in phase 3 trials. So 22C3 has most commonly been linked to pembrolizumab, 28-8 to nivolumab, and 263 used with Roche and Genentech trials primarily. And so we selected the antibodies based on the common use. We selected the scoring systems of CPS and TAP, again based on the most commonly used and validated scoring algorithms in gastric cancer. And then, although most patients in clinic and metastatic disease present with biopsy samples from the primary tumor, there may be some limitations in biopsy samples in terms of small amount of material and ability to reliably count 100 cells, etc., for CPS. So we actually use surgically resected samples from a commercial biobank, 100 samples, and essentially 28-8 was really the reference. And we picked samples that, using 28-8 CPS PD-L1 expression represented the entire spectrum, meaning we had CPS less than 1, we had greater than 1 and less than 5, greater than 5 and less than 10, and greater than 10, so that we could compare across these different strata, because those are the most common strata that have been used in clinical trials and linked to magnitude of benefit. Dr. Abdul Rafeh Naqash: And something that, interestingly, I see here when we go to some of the results, and I'm pretty sure you'll talk about the concordance, is the correlation coefficient seems to increase as the percentage positivity increases for a certain antibody. Could you try to help us understand why that might be the case? Is it because it's easier for the pathologist to look at the slide when there is a certain level of positivity that crosses a certain threshold? Or could there be some other factors that are not well understood. Dr. Samuel J. Klempner: Yeah, it's a totally good question, and I think it's something that's seen in other IHC biomarkers as well. If you look at HER2, you'll see some similar trends. The agreement at IHC 3+ is pretty good and greater than it is at lower cut points. And having talked to multiple pathologists, and I'm not a pathologist, we had three pathologists scoring all of these samples, and essentially, it's what you might expect. It is just easier when there's a lot of the marker. It is easier to judge the high extremes of the strata. So the agreement at greater than 10 is quite good, and this has already been shown by others. It's just an easier thing to score for anyone. The agreement is better across all of the assays at higher cut points, whether it's TAP greater than 10% or CPS greater than 10%. And you can see that pretty clearly in our data, and it's also been shown in other data sets looking at roughly similar questions in other tumor types.  Dr. Abdul Rafeh Naqash: Going to the interesting results that you have in this paper, could you highlight for us some of the important findings that you had and put them into context of what their clinical implications may be? Dr. Samuel J. Klempner: Yeah, I think I'll start with the clinical implications so that what clinicians, and we're both clinicians, what we want to know is, if I have a report that says the CPS is greater than 1 and it's done with a 22C3 test, is that also likely to be greater than one if it had been done with a 28-8 test or scored with a different algorithm - CPS versus TAP? So, essentially, some degree of confidence on the interchangeability between the assays themselves, that is really the clinical implication. And so, to accomplish this, we set out to basically do the comparisons you'd have to do to convince yourself that that is true. So you take samples against a reference range, in this case, across the PD-L1 strata, you pick a reference test, in this case, 28-8, you have one pathologist be the start, and then you compare other pathologists against each other and that person, and you look. And in the pathology literature, they have strata of agreement which tend to go from poor, moderate, good to excellent. And these are sort of accepted standards in the pathology world about inter reader agreement. So between one pathologist and another, and things that are moderate or good are considered essentially acceptable at interchangeable levels.  And so, as you suggested, at the higher cut points, the agreement is very good. The clinical interpretation of that is that if you get a TAP greater than 10% scored on a 22C3 antibody on a Dako staining system, you can feel relatively confident that that would also be called a TAP or a CPS greater than 10 by a 28-8 antibody, suggesting there is good agreement between the two antibodies at that cut point. As you move down, there is a little bit less agreement, and that is consistent with what's been shown before. But in our data set, the agreement was still pretty good across all three of the antibody clones, even at the lower cut point, so greater than 1% for TAP or CPS greater than 1. And that provides, I think, some reassurance to clinicians that whatever test their own pathology lab is using, if it's one of these three assays, they can provide some degree of confidence that what they're seeing would be similar to what they were seeing if it had been done with another test. Dr. Abdul Rafeh Naqash: I think that that is very important, because even though we do want broad testing in general for metastatic tumors, as you probably will agree with, but there's a lot of practices still that institutions tend to do their own testing with limited gene panels or even IHCs. So I think to put that in the context of your study, as you said, if you have a certain antibody that is positive, as you've shown, then that also likely means that with another antibody that your institution may not test for, it's likely the tumor sample is likely going to be positive at a similar level.  So I think you also used digital pathology as part of this project, even though that may not be the most important aspect. As we move slowly and steadily towards artificial intelligence and machine learning, could you tell us how you incorporated the digital assessments and how you utilize them to correlate with the pathologist assessment and the futuristic perspective of how we could eventually try to incorporate digital pathology assessments for this kind of staining approach, which might limit interobserver operability differences as well as time constraints? Dr. Samuel J. Klempner: I hope I can do this part justice, because, again, I'm not a pathologist. But the digital imaging analysis was really essentially used as a quality check and verification tool in our own paper. Our intent was not to establish DIA directly as a superior methodology to TAP or CPS, but simply to provide ourselves some degree of confidence in the staining pattern and distribution across the three assays, and whether or not this would generate significant differences in what the PD-L1 score would have been called. And so, the bottom line is, the digital imaging analysis suggested there were very minor differences across the three assays in terms of, like, percent cell positivity, which is one of the main readouts, and the mean difference was actually quite small. So we felt that the digital imaging analysis, which was really considered somewhat exploratory in our own work, supported what we saw with the pathology comparators read in traditional methods. I think it sets somewhat of an initial pilot data benchmark to say that maybe we can think about moving tools like digital imaging analyses forward in terms of PD-L1 scoring approaches in the future. But it does not provide adequate data to say that we can do this now or we have enough samples and enough comparisons to say that, “Hey, for sure, digital imaging is equivalent to pathology reading.” I think that we're getting there and our data supports that that may ultimately be the conclusion, but for us it was really essentially an orthogonal support and sanity check for our traditional approach, which is, of course, a pathologist based scoring. So supportive and suggestive, but not definitively conclusive. Dr. Abdul Rafeh Naqash: Definitely early days for visual pathology assessments, but I think that it's a very rapidly evolving field, and hopefully we'll see more of this in the next few years, as well as incorporating some assessments into clinical trials.  Now, shifting away from your honorary pathologist role as part of this project to your actual role as a clinician investigator/clinician scientist, could you tell us your career trajectory, how you started, how you've self paced yourself, and how you've tried to mentor certain different individuals in your current role? Dr. Samuel J. Klempner: Yeah, I remember my grandfather and other people telling me, just try to leave it a little bit better than you found it. And so that's, I think, a guiding principle. I hope that at the end of my own career, I can leave oncology a little bit better than when I started. I think the best way to do that is to mentor and train the next generation who are going to drive these practices. I started, like many others, personally touched by cancer in my family, which started me on a journey towards oncology, was somewhat frustrated by the lack of options available to my mom, and then became deeply interested in the science and how come we knew so little about cancer, so spent a fair amount of time in labs, and had a really formative experience with Lew Cantley looking at PI3 kinase resistance and signal transduction, and wanted to learn to speak the language and interact with people driving the lab based work. And that's been something I've tried to keep as central to my career as someone who has a very strong translational interest.  And so I try to think of ways that I think we can learn from every single patient and every subgroup. I mean, for example, in our own work here, it's very unclear if there's a biology linked to the different PD-L1 strata. So for example, does a PD-L1 CPS greater than 10 tumor have a very high interferon gene signature? Or are there features of the T cells that are different between a CPS 10 or higher versus a less than 1? So PD-L1 is a biomarker, but is it really telling us about biology? And so these are the types of questions that I try to stimulate in all the residents and fellows and hopefully it will drive translational projects. But I think just having the conversations and asking the questions and talking to people. I mean, I love the ASCO Career Lounge and always try to do that when possible. I know you do the same. I think staying curious is really the thing that I try to remain in life and also in my career and have fun and enjoy with your colleagues. And I think that will make us all better researchers and ultimately translate to better outcomes for our patients, which is, of course, why we all do this. Dr. Abdul Rafeh Naqash: Wonderfully said Sam, thank you so much. Thanks again for choosing JCO PO as the final destination for your work. Hopefully we see more of the similar work that you do in your field in JCO PO. And thank you for talking to us about your journey as well.  Dr. Samuel J. Klempner: Yes, thanks for having me. I'll talk to you sometime soon.  Dr. Abdul Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Disclosures Dr. Klempner Stock and Ownership Interests TP Therapeutics Nuvalent, Inc Honoraria Merck Serono Consulting or Advisory Role Atellas Pharma Bristol-Myers Squibb Merck Daiichi Sankyo/UCB Japan Sanofi/Aventis Mersana Exact Sciences Novartis SERVIER AstraZeneca Amgen I-Mab iho Oncology    

In this episode of "Cancer Actually F**king Sucks", we sit down with Danny, an active duty Special Agent in the U.S. Air Force and a gastric cancer survivor. Danny takes listeners on a profound journey from diagnosis to triumph, sharing how his military training prepared him for his battle against cancer. Throughout the conversation, Danny sheds light on the pivotal role of the Hunter Seven Foundation, a nonprofit aiding active duty personnel and veterans in linking their illnesses to toxic exposures during deployment. From moments of challenge to unexpected sources of hope, Danny's story epitomizes resilience in the face of adversity, the importance of family, and the power of community. Tune in for an inspiring discussion around navigating cancer as a young adult and taking page out of Ted Lasso's book by believing - believing in yourself and that you'll make it through. We hope you enjoy! Find Danny at @thrift_shop_actual on Instagram, and learn more about the HunterSeven Foundation at @huntersevenfounation, as well. Don't forget to rate and review the podcast on Spotify and Apple Podcasts, and follow us on Instagram at @canceractuallysuckspod for more inspiring content! --- Send in a voice message: https://podcasters.spotify.com/pod/show/cancer-actually-sucks/message

Join the Behind the Knife Surgical Oncology Team as we discuss the presentation, work-up, and management of gastric cancer. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Connor Chick, MD (@connor_chick) is a Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a PGY-6 General Surgery resident at Brooke Army Medical Center - Beth (Elizabeth) Carpenter, MD (@elizcarpenter16) is a PGY-5 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode, we review the basics of gastric cancer, including presentation, work-up, staging, and treatment modalities as well as high yield topics including the Siewert classification system. We also briefly discuss trials establishing peri-operative chemotherapy regimens for gastric cancer and the controversy of D1 vs. D2 lymphadenectomy. Links to Papers Referenced in this Episode Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. NEJM 2006 Jul;355(1):11-20. https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesphageal junction adenocarcinoma (FLOT4): a randomized, phase2/3 trial Lancet 2019 May;393(10184):1948-1957. https://pubmed.ncbi.nlm.nih.gov/30982686/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode, we speak with Joo Ha Hwang, MD, PhD who is a Professor of Medicine in Gastroenterology & Hepatology at Stanford University. We'll discuss why gastric cancer often goes undiagnosed until later stages, the lack of specific guidelines for screening and treatment in Asian populations, the prevalence and primary risk factors for gastric cancer, particularly H. pylori infection, with a focus on East Asians' elevated risk. Join us as Dr. Hwang shares insights on improving detection and prevention rates in this patient population. Read Transcript CME Information: https://stanford.cloud-cme.com/medcastepisode84 Claim CE and MOC: https://stanford.cloud-cme.com/Form.aspx?FormID=1910

Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal2).

This episode is hosted by Josie Baker, MS, LGC, and features Jeremy Davis, MD, a National Cancer Institute (NIH) surgical oncologist.Together, they discuss Dr. Davis' recent article published in the Journal of Medical Genetics  titled “Decision-making and regret in patients with germline CDH1 variants undergoing prophylactic total gastrectomy.”This podcast was released during  Patient Experience Week.   Read our blog post to learn more about this podcast HERE

Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/2GI).

Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.

This episode of SurgOnc Today®, recorded at SSO 2024, focuses on understanding the training and preparation needed prior to embarking on pelvic exenterative surgery and international collaboration to improve the outcomes of complex pelvic resections.

In this episode of SurgOnc Today®, Gautam Malhotra, MD, interviews Jeremy L. Davis, MD, Mio Kitano, MD, and Sonia Orcutt, MD, live at SSO 20204 after their panel discussion on “Getting the Most out of ERAS Pathways for Patients Undergoing Gastric Cancer Surgery”. They review the current literature on the use of ERAS for gastric cancer surgery, the importance of multi-disciplinary approach, and the challenges in the implementation.

- Overview of Gastric Cancer, Including Diagnosis & Staging - Current Standard of Care, Including Chemotherapy - New Treatment Approaches & the Role of Targeted Treatment & Immunotherapy - Precision Medicine: Predicting Response to Treatment - The Role of Clinical Trials - How Research Contributes to Treatment Options - Controlling Treatment Side Effects, Symptoms, Discomfort, & Pain - The Importance of Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments including: Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal).

Dr Tom Bird, Consultant Clinical Oncologist at Bristol Haematology and Oncology Centre, UK, disucsses how he treats people with gastric cancer.  We cover scenarios including both operable gastric cancer and those with recurrent and de-novo metastatic cancer including systemic agents and palliative radiotherapy.  This podcast is an overview of the current oncology treatment of gastric cancer at registrar level and is aimed at those training in oncology in the UK. Your host is Dr Alison Cameron, Consultant Clinical Oncologist, Bristol, UK.

Learn all about stomach cancer treatment, symptom management, and end-stage disease.In Part 1 we talked about risk factors, symptoms, diagnosis, staging, and survival estimates. This week for Part 2 of our discussion we review treatment options, symptom management, end-stage disease, and how you can support someone with stomach cancer.In this Episode:00:00 – Our Sponsor: Tree of Life Memorials and Digital & Stone00:20 – Intro02:18 – How to Lower Your Risk for Stomach Cancer09:50 – Recipe of the Week: Popcorn Balls12:39 – Stomach Cancer Treatment21:01 – Stomach Cancer Symptom Management33:14 – End-Stage Stomach Cancer41:49 – How to Support Someone with Stomach Cancer50:24 – Greg's Journal: The Loneliness of Caring for Someone with Alzheimer's Disease54:00- OutroFollow us on Facebook | Instagram | Email us at mail@every1dies.orgClick on this link to Rate and Review our podcast!

Lymph node dissection is a crucial component of the surgical treatment of gastric cancer. The technical aspects of lymph node dissection, especially D2, require a significant degree of training and expertise. In this episode of SurgOnc Today®, Ahmed Dehal, MD, MPH, interviews Vivian Strong, MD, from Memorial Sloan Kettering Cancer Center and Yanghee Woo, MD, from City of Hope to discuss this topic.

Featuring a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPGastroesophageal23/Part3).

Editor's Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 5, 2023, issue. Related Content: Audio Highlights

In this episode of SurgOnc Today®, Mihir M. Shah, MD, Mashaal Dhir, MD, and June S. Peng, MD, discuss the workup and management of gastric adenocarcinoma. The discussion elaborates on several scenarios, including molecular testing, surgical approaches to advanced gastric cancers, treatment sequencing, tumor-related gastric obstruction management, diagnostic laparoscopy role, perioperative management, and low-volume carcinomatosis management.

Prof Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPGastroesophageal23/Part2).

Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023GE/AudioInterview)

Everybody knows someone battling cancer. Fusobacterium nucleatum is an oral anaerobe that trans-locates to other areas of the body. It negatively impacts gut health in a number of ways including contributing to Irritable Bowel Syndrome. Initially it was found to be prevalent in human colorectal cancer (CRC) where it is associated with poor treatment outcomes. It is being widely studied and found to be associated with a growing number of cancers. Recent research is showing that this oral pathogen may induce resistance to several chemotherapy drugs.  The good news is that we can test for it and treat it relatively simply. This is information that can increase your vitality, improve your relationships, and take the stress out of being healthy!References:Fusobacterium nucleatum confers chemoresistance by modulating autophagy in esophageal squamous cell carcinoma (December, 2020)https://www.nature.com/articles/s41416-020-01198-5 Fusobacterium nucleatum:  a new player in regulation of cancer development and therapeutic response (May, 2022)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255244/  Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer (January, 2019) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327560/ Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression (June, 2020)https://www.nature.com/articles/s41467-020-16967-2 Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer (February, 2023) https://www.cell.com/trends/microbiology/fulltext/S0966-842X(22)00222-0 The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences?  A systematic review  (April, 2021) https://pubmed.ncbi.nlm.nih.gov/33823861/ Could Periodontal Disease through Periopathogen Fusobacterium nucleatum Be an Aggravating Factor for Gastric Cancer?  (December, 2020) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761398/ More Than Just a Periodontal Pathogen – the Research Progress on Fusobacterium nucleatum (February, 2022) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851061/ 

This episode is hosted by Josie Baker, MS, CGC, a genetic counselor at The Ohio State University, and features Rachael Lopez, MPH, RD, CSO, a clinical research dietitian at the National Institutes of Health. Together they discuss the considerations for individuals with Hereditary Diffuse Gastric Cancer Syndrome when considering a prophylactic gastrectomy. This episode highlights the professional experience when working with these individuals before and after surgery, as well as the challenges individuals may face during this process.